Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951764 | 0.98 | DGAT1 (0.37) | DGAT1HDAC1HDAC6 | |
| SCHEMBL953732 | 0.95 | DGAT1 (0.36) | DGAT1HDAC1HDAC6 | |
| SCHEMBL24306335 | 0.80 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL1811528 | 0.79 | ALOX5AP (0.33) | DGAT1 | |
| SCHEMBL23939802 | 0.79 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL29961918 | 0.79 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL3508159 | 0.78 | DGAT1 (0.40) | DGAT1HDAC1HDAC6 | |
| SCHEMBL28434865 | 0.76 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL16847388 | 0.76 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL19284804 | 0.76 | DGAT1 (0.31) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451800-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | Vivalis (FR) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011004017-A1 | 1-(6 MEMBERS AZO-HETEROCYCLIC)-PYRROLIN-2-ONE COMPOUNDS AS INHIBITORS OF HEPATITIS C NS5B POLYMERASE, THE PHARMACEUTICAL COMPOSITION THEREOF AND THEIR THERAPEUTIC USE | VIVALIS (FR) | 2011-01-13 | — | — | WO | disclosed |